Intermountain Healthcare to offer Galleri cancer blood test

By LabPulse.com staff writers

May 18, 2022 -- Utah-based health system Intermountain Healthcare will be offering Grail’s Galleri multicancer early detection blood test as a complement to existing single-cancer screenings.

Grail's test will be available beginning this month to Intermountain health system patients who are at elevated risk for cancer, such as adults ages 50 and older or those with additional risk factors, according to Grail. Furthermore, eligible employees and their families who are enrolled in a company-sponsored health plan will also be able to receive a test from Intermountain.

Illumina sees revenue increases for Q1 as net income slips
Strong growth across multiple business units helped DNA sequencing developer Illumina report revenue increases for the first quarter of fiscal 2022 (end-April...
Illumina brings whole-genome sequencing to German hospital
Illumina has signed an agreement with Hannover Medical School in Germany to assess the use of rapid whole-genome sequencing (rWGS) in critically ill children...
Grail to partner with Premier
Grail has signed a collaborative agreement with Premier to use that company's PINC AI technology and services platform to expand patient access to Grail's...
Illumina appoints Ragusa as CEO of Grail
Illumina has appointed Bob Ragusa as CEO of Grail, which currently operates as a separate and independent unit of Illumina after its August acquisition.
Illumina completes Grail deal, despite lack of European approval
Illumina has completed its acquisition of cancer diagnostics developer Grail, almost a year after announcing the deal. Illumina said it would run Grail...

Copyright © 2022 LabPulse.com

Last Updated mp 5/18/2022 8:18:42 AM